-
Je něco špatně v tomto záznamu ?
The "Five risks algorithm": an easy tool for cardiovascular risk estimation
Dirk Devroey, Jan Vandevoorde
Jazyk angličtina Země Česko
Digitální knihovna NLK
Plný text - Článek
Číslo
Ročník
Zdroj
Zdroj
NLK
Free Medical Journals
od 2004
ProQuest Central
od 2009-03-01 do Před 6 měsíci
Medline Complete (EBSCOhost)
od 2006-03-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest)
od 2009-03-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 2009-03-01 do Před 6 měsíci
Public Health Database (ProQuest)
od 2009-03-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources
od 1993
PubMed
20020602
DOI
10.21101/cejph.b0016
Knihovny.cz E-zdroje
- MeSH
- algoritmy MeSH
- diabetes mellitus MeSH
- hodnocení rizik MeSH
- hypercholesterolemie diagnóza farmakoterapie MeSH
- hypertenze MeSH
- hypolipidemika terapeutické užití MeSH
- kardiovaskulární nemoci prevence a kontrola MeSH
- lidé středního věku MeSH
- lidé MeSH
- senzitivita a specificita MeSH
- validační studie jako téma MeSH
- výběr pacientů MeSH
- zdravotnické přehledy MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
The aim of this study is to provide an easy tool to identify patients with a high cardiovascular risk, especially those qualifying for lipid-lowering treatment. The decision to treat with lipid-lowering drugs was assessed with five new risk algorithms. The Five Risk algorithm (5R) takes into account male gender, high systolic blood pressure, high total cholesterol, smoking and high blood sugar as independent risk factors. Patients with three independent risk factors qualify for lipid-lowering treatment. Compared to the Framingham Risk Score, the 5R has a Kappa coefficient of 0.62. Compared to the SCORE, the Six Risk algorithm (6RDF) has a Kappa coefficient of 0.70. The 6RDF uses only four independent risk factors (male gender, high systolic blood pressure, high total cholesterol and smoking) but having diabetes or a family history of premature coronary heart disease are exclusion criteria for which treatment with lipid-lowering drugs is always indicated.
Citace poskytuje Crossref.org
Lit.: 29
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07532316
- 003
- CZ-PrNML
- 005
- 20111210152329.0
- 008
- 100930s2009 xr e eng||
- 009
- AR
- 024 7_
- $a 10.21101/cejph.b0016 $2 doi
- 035 __
- $a (PubMed)20020602
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Devroey, Dirk
- 245 14
- $a The "Five risks algorithm": an easy tool for cardiovascular risk estimation / $c Dirk Devroey, Jan Vandevoorde
- 314 __
- $a Department of General Practice, Vrije Universiteit Brussel, Brussels
- 504 __
- $a Lit.: 29
- 520 9_
- $a The aim of this study is to provide an easy tool to identify patients with a high cardiovascular risk, especially those qualifying for lipid-lowering treatment. The decision to treat with lipid-lowering drugs was assessed with five new risk algorithms. The Five Risk algorithm (5R) takes into account male gender, high systolic blood pressure, high total cholesterol, smoking and high blood sugar as independent risk factors. Patients with three independent risk factors qualify for lipid-lowering treatment. Compared to the Framingham Risk Score, the 5R has a Kappa coefficient of 0.62. Compared to the SCORE, the Six Risk algorithm (6RDF) has a Kappa coefficient of 0.70. The 6RDF uses only four independent risk factors (male gender, high systolic blood pressure, high total cholesterol and smoking) but having diabetes or a family history of premature coronary heart disease are exclusion criteria for which treatment with lipid-lowering drugs is always indicated.
- 650 _2
- $a algoritmy $7 D000465
- 650 _2
- $a hypolipidemika $x terapeutické užití $7 D000960
- 650 _2
- $a kardiovaskulární nemoci $x prevence a kontrola $7 D002318
- 650 _2
- $a diabetes mellitus $7 D003920
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a zdravotnické přehledy $7 D006306
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypercholesterolemie $x diagnóza $x farmakoterapie $7 D006937
- 650 _2
- $a hypertenze $7 D006973
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a výběr pacientů $7 D018579
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a senzitivita a specificita $7 D012680
- 650 _2
- $a validační studie jako téma $7 D054928
- 700 1_
- $a Vandevoorde, Jan
- 773 0_
- $w MED00001083 $t Central European journal of public health $g Roč. 17, č. 3 (2009), s. 133-138 $x 1210-7778
- 910 __
- $a ABA008 $b B 1829 $c 562 $y 8
- 990 __
- $a 20091101102934 $b ABA008
- 991 __
- $a 20100930093552 $b ABA008
- 999 __
- $a ok $b bmc $g 691177 $s 553068
- BAS __
- $a 3
- BMC __
- $a 2009 $b 17 $c 3 $d 133-138 $i 1210-7778 $m Central European Journal of Public Health $x MED00001083
- LZP __
- $a 2009-51/ipme